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Intraocular angiogenesis is considered the leading cause for severe loss of vision, and contributes to
many ocular diseases such as neovascular age-related macular degeneration, diabetic retinopathy, and
retinopathy of prematurity, the main causes of blindness in developed countries.1 An enormous body of
work has demonstrated that vascular endothelial growth factor (VEGF) plays a prominent role as
mediator in the procedure of pathological angiogenesis. This makes VEGF a potential target for the
medical therapies of retinal angiogenesis and some clinical trials have proved the efﬁcacy of anti-VEGF
strategies. This review evaluates the role of VEGF in the pathogenesis of age-related macular degener-
ation and provides an overview of recent developments in therapeutic modalities.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Angiogenesis is deﬁned as the growth of new blood vessels from
existing blood vessels. In normal circumstances, new blood vessels
develop and this is considered a positive response of normal bio-
logic functions such as hair growth, wound healing, menstruation,
and regulation of blood pressure in adults.1e4 The execution of this
complex angiogenesis cascade needs a precise physiological bal-
ance between proangiogenic and antiangiogenic factors. Once
proangiogenic factors prevail, endothelial cells begin to proliferate,
migrate, differentiate, and may induce capillary formation and
several pathological processes happen, such as tumor growth,
rheumatoid arthritis, and age-relatedmacular degeneration (AMD).
To date, several proangiogenic factors have been identiﬁed
including vascular endothelial growth factor (VEGF), ﬁbroblast
growth factor families, and transforming growth factor.3,5,6 One of
the most potent proangiogenic factors is VEGF.
2. VEGF and its receptors
VEGF is a 40 kDa, homodimeric glycoprotein, speciﬁc for
vascular endothelial cells and able to induce vasculogenesis and, Pﬁzer, Santen and Bayer.
mology, Shiga University of
2192, Japan.
e Ophthalmologic Society of Taiwangiogenesis.7 VEGF is an endothelial cell mitogen, promoting
endothelial cell growth and survival and increases vascular
permeability in vivo.6,8 It is essential for angiogenesis during early
embryogenesis and the loss of one single allele of the VEGF gene
may lead to embryonic lethality.9 In the VEGF family, there are
seven members: VEGF-A (hereafter referred to as VEGF), VEGF-B,
VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor.
Among these factors, VEGF has been studied most widely. In
humans, the VEGF gene is located on the short arm of chromosome
6 (6p21.1) and organized into eight exons, separated by seven in-
trons.10,11 Alternative splicing of the pre-mRNA leads to the gen-
eration of several different isoforms named as VEGFxxx (xxx
denotes the number of amino acids) with same exons 1e5 and
various combinations of exons 6e8. The principal ones include
VEGF121, VEGF165, VEGF189, and VEGF206.11 All extracellular VEGF
isoforms are cleaved by plasmin to VEGF110.12,13
Recently, it was discovered that VEGF alternative splicing in
exon 8 generated sister isoforms, producing proteins with the same
length, but with a different C-terminal amino acid sequence. This
family has been termed VEGFxxxb.14 Because VEGFxxxb has been
shown to be able to inhibit VEGFxxx-dependent angiogenesis, it has
been tested in patients with diabetic retinopathy and retinal vein
occlusion, and a mouse model of oxygen-induced retinopathy.15e17
A VEGF splicing switch was observed, from an antiangiogenic
VEGFxxxb to a proangiogenic VEGFxxx environment, which may
indicate that changing the ratio of VEGFxxxb/VEGFxxx could be a
potential therapy for treating ocular angiogenesis diseases.an. Published by Elsevier Taiwan LLC. All rights reserved.
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kinase type have been identiﬁed: VEGFR-1 (Flt-1 or fms-like tyro-
sine kinase) and VEGFR-2 (kinase insert domain-containing re-
ceptor or KDR) are mainly involved with angiogenesis18e20; and
VEGFR-3 (fms-like tyrosine kinase-4 or Flt-4) is a receptor for VEGF-
C and VEGF-D, which are involved in lymphangiogenesis.20e213. VEGF in AMD
AMD is one of the leading causes of irreversible blindness in
people aged 55 years and older in developed countries.22e25 It can
be classiﬁed into two types: atrophic (dry) and neovascular (wet).
The more severe neovascular form (nAMD) accounts for approxi-
mately 90% to legal blindness and is characterized by choroidal
neovascularization (CNV) which can intrude into the subretinal
space, leading to hemorrhage and exudation.26 Neovascular AMD
often has a poor prognosis, leading to a rapid vision loss. It can
deeply affect the quality of life of patients. So far the precise
mechanism of AMD is still unclear, but VEGF is thought to be a
potent mediator contributing to CNV.27 As a possible path for
pathogenesis of CNV in AMD, it is suggested that VEGF plays a
major part at the initial stage of CNV by promoting angiogenesis
and is a mitogen speciﬁc for endothelial cells as part of the angio-
genesis pathway, inducing their differentiation.28 In addition, VEGF
also increases vascular permeability by breaking the vascular
endothelial cells’ junction, which results in over-secretion of ﬂuid,
proteins, and circulating cells and destroys the retinal anatomy,
making the retina detach from the basement,29 leading to the loss
of vision.
In 1996, the relationship of VEGF and neovascular AMD was
reported by two groups, who identiﬁed VEGF localized in ﬁbro-
blastic cells and choroidal neovascular membranes and suggested a
crucial role of VEGF in the development of the choroidal neo-
vascularization in nAMD patients.30,31 As well as in rodent models,
VEGF was found to be expressed in laser-induced CNV.32 In addi-
tion, many investigators have tested that the VEGF concentration of
ocular ﬂuid in human eyes with AMD elevates signiﬁcantly
compared with normal eyes.33e37 Some experiments have shown
that suppression of VEGF can restrain the progress of CNV. Inhibi-
tion of VEGF has been associated with an inhibition of iris neo-
vascularisation and suppression of the formation of new retinal
vessels in primates.38 There is strong evidence that, in AMD pa-
tients, both VEGF121 and VEGF165 are expressed in excised CNV
membranes.394. VEGF inhibitors and VEGF concentration in patients with
nAMD
Because there is considerable evidence to suggest that VEGF
plays a major role in pathological angiogenesis, it has become aTable 1
Differences among anti-vascular endothelial growth factor (VEGF) drugs.
Pegaptanib sodium Ranibizumab
Molecular weight, kDa 50 40
Vitreous half-life, d Rabbit: 3.542 Rabbit: 2.8844
Human: 1043 Human: 945
Afﬁnity (Kd)b, pMc 200 46
Technology Oligonucleotide-aptamer Monoclonal antibody fragm
Target VEGF165 All isoforms of VEGF
Presence of Fc No No
a Regeneron, Tarrytown, NY, USA: data on ﬁle.
b Kd: dissociation constant.
c pM: unit of afﬁnity, 1 pM = 1012 mol/L.suitable target to treat neovascular AMD. So far, three anti-VEGF
agents (pegaptanib sodium, ranibizumab, aﬂibercept) have been
approved for AMD by the Food and Drug Administration (FDA).
These drugs were developed for inhibiting VEGF-A by different
approaches.5. Pegaptanib sodium
Pegaptanib sodium (Macugen; EyeTech, New York, NY, USA) was
the ﬁrst approved anti-VEGF drug for treating nAMD by intravitreal
injection; its molecular weight is approximately 50 kDa. It is an
pegylated, 28-base RNA aptamer speciﬁc to inhibit VEGF165 isoform
(Table 1).40e47 In two pivotal clinical trials, the efﬁcacy of pegap-
tanib sodium for the treatment of CNV secondary to AMD were
evaluated (VEGF Inhibition Study In Ocular Neovascularisation:
VISION). Although patients in the pegaptanib sodium injection
group lost less letters compared with a sham injection group at 1
year (p < 0.002), they did not maintain the visual acuity (VA) by
pegaptanib sodium treatment.48 However, in the LEVEL study and
the LEVEL-J study, pegaptanib sodium showed its effect on
improving VA after induction treatments of nonselective VEGF-
inhibitor or photodynamic therapy for a 1-year maintenance
period.49,50
In animal models, pegaptanib sodium is cleared from the eye
with an estimated vitreous half-life of 3.9 days after intravitreal
administration and accumulation of pegaptanib sodium in the
plasma was not found.42 In our previous study, we reported that
intravitreal injection of pegaptanib sodium increased VEGF level in
aqueous humor at 6 weeks after injection.35 This result was un-
expected because pegaptanib sodium is designed to suppress
VEGF165, but could be explained by an increase in VEGF121 isoform
as we explained in the study. Based on the recent new ﬁnding of
VEGF antiangiogenic VEGFxxxb isoforms, another potential reason
has emerged. In the 6-week follow-up after injection, pegaptanib
sodium may have the effect of increasing VEGFxxxb, returning
VEGFxxxb/VEGFxxx balance to level, whichmay contribute to normal
ocular circumstance. This hypothesis needs to be veriﬁed in future
studies, but there is no signiﬁcant change of plasma VEGF levels
observed in patients receiving pegaptanib sodium injection during
1 month follow-up.51 That may account for the small molecular
weight and fast clearance of pegaptanib sodium in systemic cir-
culation, also conﬁrmed by the pegaptanib sodium pharmacoki-
netics result in the animal experiment.426. Ranibizumab
Ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA,
USA) is a humanized, recombinant, monoclonal antibody Fab
fragment binding to all isoforms of VEGF. Molecular weight is
48 kDa. It was approved by the FDA for treating nAMD in 2006Aﬂibercept Bevacizumab
115 149
Rabbit: 4.7daysa Rabbit: 4.3246
Human: no data Human: 947
0.5 58
ent Fusion Protein Full-length monoclonal antibody
All isoforms of VEGF and VEGF-B,
placental growth factor
All isoforms of VEGF
Yes Yes
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prevent visual loss but also increase mean VA after 2 years in pa-
tients with all types of CNV secondary to AMD. The efﬁcacy and
safety of ranibizumab in all types of AMD related CNV have beenFig. 1. Mean change of best-corrected visual acuity (BCVA) from several clinical trials. (A) AN
(F) CATT study. Note. Fig. 1A is from “Ranibizumab versus verteporﬁn photodynamic therap
study”, by DM Brown, M Michel, PK Kaiser, JS Heier, JP Sy, T Ianchulev, et al, 2009, Ophtha
“Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-re
Yue, T Ianchulev, S Schneider, et al, 2008, Am J Ophthalmol 145, p. 243. Copyright 2008, Else
quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCI
Axer-Siegel, et al, 2011, Ophthalmology, 118, p. 835. Copyright 2011, Elsevier. Reprinted with p
neovascular age-related macular degeneration: year 2 of the PrONTO Study”, by GA Lalwan, P
46, Copyright 2009, Elsevier. Reprinted with permission. Fig. 1E is from “Safety and efﬁc
degeneration: the SUSTAIN study”, by FG Holz, W Amoaku, J Donate, RH Guymer, U Kellner,
with permission. Fig. 1F is from “Ranibizumab and bevacizumab for treatment of neovascul
Macular Degeneration Treatments Trials (CATT) Research Group, DF Martin, MG Maguire, SL
Reprinted with permission.veriﬁed in view of two phase III clinical trials.52e54 On average,
patients after intravitreal ranibizumab administration gained 1e2
lines VA in the ﬁrst year of treatment (Fig. 1A). Ranibizumab was
considered as the ﬁrst VEGF antagonist able to improve VA inCHOR study, (B) PIER study, (C) EXCITE study, (D) PrONTO study, (E) SUSTAIN study, and
y for neovascular age-related macular degeneration: Two-year results of the ANCHOR
lmology, 116, p. 61. Copyright 2009, Elsevier. Reprinted with permission. Fig. 1B is from
lated macular degeneration: PIER Study year 1”, by CD Regill, DM Brow, P Abraham, H
vier. Reprinted with permission. Fig. 1C is from “Efﬁcacy and safety of monthly versus
TE study”, by U Schmidt-Erfurt, B Eldem, R Guymer, JF Korobelnik, RO Schlingemann, R
ermission. Fig. 1D is from “A variable-dosing regimen with intravitreal ranibizumab for
J Rosenfel, AE Fung, SR Dubovy, S Michels, W Feuer, et al, 2009, Am J Ophthalmol, 148, p.
acy of a ﬂexible dosing regimen of ranibizumab in neovascular age-related macular
RO Schlingemann, 2011, Ophthalmology 118, p. 668. Copyright 2011, Elsevier. Reprinted
ar age-related macular degeneration: two-year results”, by Comparison of Age-related
Fine, GS Ying, GJ Jaffe, et al, 2012, Ophthalmology, 119, p. 1391. Copyright 2012, Elsevier.
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humor of eyes with AMD can be suppressed 1 month after intra-
vitreal administration of ranibizumab.33e35 Although VEGF con-
centration in plasma of patients with nAMD presented different
phenomenon,51,55,56 no signiﬁcant suppression of plasma VEGF
levels were observed in patients receiving ranibizumab for 1
month.
However, a monthly injection may bring the risk of intraocular
infection and heavy economic burden to patients. Therefore, some
researchers administrated a less frequent regimen to treat AMD. In
the Phase IIIb, multicenter, randomized, double-masked, sham in-
jection– controlled study of the efﬁcacy and safety of ranibizumab
in subjects with subfoveal CNV with or without classic CNV sec-
ondary to AMD (PIER) study, quarterly injections following three
consecutive monthly injections were given. Although clinically
meaningful VA beneﬁt was gained by the ranibizumab group
compared with the sham group, mean VA improved from baseline
only lasted 3 months with monthly ranibizumab injection and it
declined during the 21-monthmaintenance phase (Fig.1B).57,58 The
EXCITE study also used the quarterly injection regimen in the
maintenance stage and compared with monthly injection directly.
However, at the end of this study, quarterly injection showed
inferiority to monthly injection in spite of increased VA, which
demonstrates that more frequent monitoring is needed (Fig. 1C).59
The Prospective OCT Imaging of Patients with Neovascular AMD
Treated with intra Ocular Ranibizumab (PrONTO) study adopted an
optical coherence tomography-guided, variable dosing regimen
after three monthly loading doses for the treatment of nAMD,
which resulted in similar VA beneﬁt as the Anti-vascular endo-
thelial growth factor (VEGF) Antibody for the Treatment of Pre-
dominantly Classic Choroidal Neovascularization in Age-related
Macular Degeneration (ANCHOR) and the Minimally classic/occult
trial of the Anti-VEGF antibody Ranibizumab In the treatment of
Neovascular Age-related macular degeneration studies and with
fewer injections (Fig. 1D).60,61 In SUSTAIN, another phase III,
multicenter, open-label, single-arm study, monthly monitoring and
individualized retreatment based on VA and OCT ﬁndings after
three monthly injections showed VA improvement of 3.6 letters
with fewer injections (Fig. 1E).62 The Safety Assessment of Intra-
vitreous Lucentis for AMD (SAILOR) study also brought VA
improvement of 2.3 letters with quarterly monitoring but was
inferior to the result of monthly injection.63 Head-to-head ranibi-
zumab and bevacizumab trials (Comparison of Age-Related Macu-
lar Degeneration Treatments Trials: CATT) reported that monthly
injection of ranibizumab gained 8.8 letters at 24 months, which is
signiﬁcantly higher than the pro re nata regimen of ranibizumab’s
6.7 letters (Fig. 1F).64 The Presented within are the 12-month re-
sults of the pHase III, double-masked, multicenter, randomized,
Active treatment-controlled study of the efﬁcacy and safety of 0.5
mg and 2.0 mg Ranibizumab administered monthly or on an as-
needed Basis (PRN) in patients with subfoveal neOvasculaR age-
related macular degeneration (HARBOR) study also demonstrated
that monthly injection of 0.5 mg ranibizumab provides optimum
results in patients with nAMD.65 According to the studies above,
monthly intravitreal injection of ranibizumab seems to be the best
regimen for the treatment of nAMD. Recently we conducted a 6-
month pilot study of bimonthly intravitreal injection of ranibizu-
mab for AMD patients. In the preliminary result, the mean BCVA in
logMAR kept improving from baseline until 6 months. (0.50 at
baseline, 0.46 at 1 month, 0.44 at 2 months, 0.39 at 3 months, 0.36
at 4months, 0.37 at 5months, and 0.33 at months) and a signiﬁcant
difference was seen at 4 months, 5 months, and 6 months
(p < 0.05). The mean central retinal subﬁeld thickness was 316 mm
at baseline, 239 mm at 1 month, 262 mm at 2 months, 242 mm at 3
months, 255 mm at 4 months, 256 mm at 5 months, and 275 mm at 6months. It decreased signiﬁcantly at 1 month, 3 months, and 5
months compared with baseline (p < 0.05).66 Our results demon-
strate that bimonthly injection also beneﬁts both anatomy and
function, and is evidence that bimonthly intravitreal injection could
be a choice for the treatment of nAMD.
7. Aﬂibercept
Aﬂibercept (Eylea; Regeneron Pharmaceuticals, New York, NY,
USA) is a fusion protein with high-afﬁnity, combining the second
domain of human VEGFR-1 and the third domain of human VEGFR-
2 fused to the Fc portion of human immunoglobulin (Ig)G (Table 1).
Unlike pegaptanib, ranibizumab, and bevacizumab, aﬂibercept
blocks all VEGF isoforms, VEGF-B and placental growth factor.67 Up
to now, there are no studies in human eyes demonstrating the half-
life of aﬂibercept; however, the high afﬁnity and the similar mo-
lecular weight (115 kDa) suggest that aﬂibercept’s ocular half-life
would be similar to bevacizumab (approximately 9 days in hu-
man vitreous).47 One intravitreal injection of 2 mg aﬂibercept
would last between 48 days and 83 days, whereas ranibizumab
lasts 30 days, estimated by mathematical modeling.68 This was also
conﬁrmed by the VEGF Trap-Eye: Investigation of Efﬁcacy and
Safety in Wet AMD [VIEW 1, VIEW 2] trials. In these two parallel,
phase III, double-masked, randomized, multicenter studies, the
efﬁcacy of bimonthly injection of aﬂibercept following three
loading doses of 2mg aﬂibercept showed to be noninferior over a 1-
year period when compared with the gold standard monthly in-
jection of ranibizumab. There are no differences in systemic or
ocular safety among groups. This not only reduces the risk from
monthly intravitreal injections but also the economic and psycho-
logical burden.
8. Bevacizumab
Bevacizumab (Avastin; Genentech) is a recombinant humanized
monoclonal IgG antibody against VEGF with molecular weight of
149 kDa that binds and neutralizes all human VEGF-A isoforms
(Table 1). It is approved by the FDA for intravenous administration
for the treatment of metastatic colorectal cancer.69 Although bev-
acizumab was used as an off-label drug for nAMD patients, prob-
ably because it is less expensive than ranibizumab, it has shown to
be effective and well tolerated in short term,70e73 despite the
absence of data from randomized clinical trials supporting its use.74
Recently, the randomized clinical CATT assessed the efﬁcacy and
safety of ranibizumab and bevacizumab in both monthly and as
needed (PRN) regimens for nAMD.64 At the end of the second year,
patients who receivedmonthly intravitreal injection of ranibizumab
gained a mean of 8.8 letters which showed no signiﬁcant difference
compared to 7.8 letters of monthly injection of bevacizumab (p ¼
0.21). PRN injection of either drug gained less visual acuity compared
with monthly regimen (ranibizumab, 6.7 letters; bevacizumab, 5.0
letters, p¼ 0.046). However, bevacizumabhadhigher rates of serious
systemic adverse events than ranibizumab. It has been reported that
plasma VEGF level was 89.7 pg/mL in nAMD patients and it signiﬁ-
cantlydecreased to25.1pg/mLafter1week (p¼0.01), and to22.8pg/
mL after 1 month (p ¼ 0.008).51 In Carneiro’s study,75 bevacizumab
could suppress plasma VEGF for up to 1 month in nAMD patients
(p< 0.001).Whether the lack of speciﬁcity to conditions is associated
with inhibition of VEGF requires further study.64
9. Summary
The development of therapeutic approaches that aim to inhibit
VEGFand suppress angiogenesis has heralded a newera and become
a landmark in the history of treatment for nAMD. This new therapy
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of patients with nAMD. However, it must be considered that VEGF
also has its physiological function in human development, such as
wound healing, regulation of angiogenesis and blood viscosity, pro-
moting neuronal survival, and anti-inﬂammatory effects.2,6,76e79
Suppression of VEGF may result in thrombosis, hemorrhage,
inﬂammation, andvasoconstriction. The long-termeffect of systemic
VEGF inhibition is always an interest topic and debate in both sci-
entiﬁc and clinical domains. Future studies and surveillance of long-
term safety is required. More new agents to treat nAMD will be
invented in the future and patientswill also beneﬁt fromgreater and
longer efﬁcacy of the combination of different therapies.References
1. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-
mediated angiogenesis. J Clin Invest 2001;107:409e17.
2. Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM.
Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt
1993;92:258e72.
3. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, et al.
Vascular endothelial growth factor is essential for corpus luteum angiogenesis.
Nat Med 1998;4:336e40.
4. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and
angiogenesis. Curr Pharm Des 2003;9:1733e44.
5. Ferrara N. Role of vascular endothelial growth factor in physiologic and path-
ologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10e4.
6. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial
growth factor is a secreted angiogenic mitogen. Science 1989;246:1306e9.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic
switch during tumorigenesis. Cell 1996;86:353e64.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med
2003;9:669e76.
9. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, et al. Hetero-
zygous embryonic lethality induced by targeted inactivation of the VEGF gene.
Nature 1996;380:439e42.
10. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The
human gene for vascular endothelial growth factor. Multiple protein forms are
encoded through alternative exon splicing. J Biol Chem 1991;266:11947e54.
11. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endo-
thelial growth factor family: identiﬁcation of a fourth molecular species and
characterization of alternative splicing of RNA.Mol Endocrinol 1991;5:1806e14.
12. Kaiser PK. Antivascular endothelial growth factor agents and their develop-
ment: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:
660e8.
13. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, et al. The
carboxylterminal domain (111e165) of vascular endothelial growth factor is
critical for its mitogenic potency. J Biol Chem 1996;271:7788e95.
14. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al.
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is
downregulated in renal cell carcinoma. Cancer Res 2002;62:4123e31.
15. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic
retinopathy is associated with a switch in splicing from anti- to pro-angiogenic
isoforms of vascular endothelial growth factor. Diabetologia 2005;48:2422e7.
16. Ehlken C, Rennel ES, Michels D, Grundel B, Pielen A, Junker B, et al. Levels of
VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal
vein occlusion. Am J Ophthalmol 2011;152:298e303.
17. Zhao M, Shi X, Liang J, Miao Y, Xie W, Zhang Y, et al. Expression of pro- and
anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced
retinopathy. Exp Eye Res 2011;93:921e6.
18. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, et al.
Nucleotide sequence and expression of a novel human receptor-type tyrosine
kinase (ﬂt) closely related to the fms family. Oncogene 1990;5:519e24.
19. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC,
Gospodarowicz D, et al. Identiﬁcation of the KDR tyrosine kinase as a receptor
for vascular endothelial cell growth factor. Biochem Biophys Res Commun
1992;187:1579e86.
20. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA.
VEGF activation of protein kinase C stimulates occludin phosphorylation and
contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006;47:
5106e15.
21. Blume-Jensen P,Hunter T. Oncogenic kinase signalling.Nature2001;411:355e65.
22. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-speciﬁc preva-
lence and causes of blindness and visual impairment in an older population:
the Rotterdam Study. Arch Ophthalmol 1998;116:653e8.
23. Bressler NM. Age-related macular degeneration is the leading cause of blind-
ness. JAMA 2004;291:1900e1.
24. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al.
Prevalence of age-related macular degeneration in the United States. Arch
Ophthalmol 2004;122:564e72.25. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP,
et al. Global data on visual impairment in the year 2002. Bull World Health
Organ 2004;82:844e51.
26. Patz A. Clinical and experimental studies on retinal neovascularization. XXXIX
Edward Jackson Memorial Lecture. Am J Ophthalmol 1982;94:715e43.
27. Aiello LP. Vascular endothelial growth factor: 20th-century mechanisms, 21st-
century therapies. Invest Ophthalmol Vis Sci 1997;38:1647e52.
28. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated
retinal pigment epithelial cells are immunoreactive for vascular endothelial
growth factor in surgically excised age-related macular degeneration-related
choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855e68.
29. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal ﬁbrovascular membranes
in age-related macular degeneration express vascular endothelial growth
factor. Invest Ophthalmol Vis Sci 1996;37:1929e34.
30. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K, et al. Vascular
endothelial growth factor expression in choroidal neovascularization in rats.
Graefes Arch Clin Exp Ophthalmol 1997;235:313e9.
31. Jonas JB, Neumaier M. Vascular endothelial growth factor and basic ﬁbroblast
growth factor in exudative age-related macular degeneration and diffuse dia-
betic macular edema. Ophthalmic Res 2007;39:139e42.
32. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, et al. Levels of
vascular endothelial growth factor are elevated in the vitreous of patients with
subretinal neovascularisation. Br J Ophthalmol 1996;80:363e6.
33. Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and
pigment epithelium-derived factor after ranibizumab alone or combined with
verteporﬁn for exudative age-related macular degeneration. Am J Ophthalmol
2009;148:718e24.
34. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, et al. Neovascular
age-related macular degeneration: intraocular cytokines and growth factors
and the inﬂuence of therapy with ranibizumab. Ophthalmology 2009;116:
2393e9.
35. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Aqueous
vascular endothelial growth factor after intravitreal injection of pegaptanib or
ranibizumab in patients with age-related macular degeneration. Retina
2010;30:1034e8.
36. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of
retinal neovascularization in vivo by inhibition of vascular endothelial growth
factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci
U S A 1995;92:10457e61.
37. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al.
Inhibition of vascular endothelial growth factor prevents retinal ischemia-
associated iris neovascularization in a nonhuman primate. Arch Ophthalmol
1996;114:66e71.
38. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al. Placental
growth factor, a member of the VEGF family, contributes to the development of
choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186e93.
39. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP,
et al. Augmentation of transvascular transport of macromolecules and nano-
particles in tumors using vascular endothelial growth factor. Cancer Res
1999;59:4129e35.
40. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 in-
hibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim
1999;35:533e42.
41. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-
VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related
macular degeneration. Retina 2002;22:143e52.
42. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, et al. Pharmaco-
kinetics and safety of an anti-vascular endothelial growth factor aptamer
(NX1838) following injection into the vitreous humor of rhesus monkeys.
Pharm Res 2000;17:1503e10.
43. Patel M, Whitﬁeld L, Hutmacher M, Kowalski K, Burger P, Dessalegn B, et al.
Population pharmacokinetics/pharmacodynamics (PK/PD) of pegaptanib so-
dium (Macugen) in patients with agerelated macular degeneration (AMD). In:
Association for Research in Vision and Ophthalmology 2006. Program. A2623.
44. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of
intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179e82.
45. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of rani-
bizumab in patients with neovascular age-related macular degeneration: a
population approach. Invest Ophthalmol Vis Sci 2013;54:1616e24.
46. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intra-
vitreal bevacizumab (Avastin). Ophthalmology 2007;114:855e9.
47. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single
intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina
2011;31:1877e84.
48. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR., VEGF
Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegapta-
nib for neovascular age-related macular degeneration. N Engl J Med
2004;351:2805e16.
49. Friberg TR, Tolentino M; LEVEL Study Group, Weber P, Patel S, Campbell S, et al.
Pegaptanib sodium as maintenance therapy in neovascular age-related mac-
ular degeneration: the LEVEL study. Br J Ophthalmol 2010;94:1611e7.
50. Ishibashi T., on behalf of the LEVEL-J Study Group. Maintenance therapy with
pegaptanib sodium for neovascular age-related macular degeneration: an
exploratory study in Japanese patients (LEVEL-J study). Jpn J Ophthalmol
2013;57:417e23.
X. Wang, M. Ohji / Taiwan Journal of Ophthalmology 3 (2013) 128e133 13351. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of
vascular endothelial growth factor before and after intravitreal injection of
bevacizumab, ranibizumab and pegaptanib in patients with age-related mac-
ular degeneration, and in patients with diabetic macular oedema. Br J Oph-
thalmol 2013;97:454e9.
52. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Rani-
bizumab for neovascular age-related macular degeneration. N Engl J Med
2006;355:1419e31.
53. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibi-
zumab versus verteporﬁn for neovascular age-related macular degeneration.
N Engl J Med 2006;355:1432e44.
54. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab
versus verteporﬁn photodynamic therapy for neovascular age-related macular
degeneration: two-year results of the ANCHOR study. Ophthalmology
2009;116:57e65.
55. Machalinska A, Paczkowska E, Pabin T, Safranow K, Karczewicz D,
Machaliñski B. Inﬂuence of ranibizumab on vascular endothelial growth factor
plasma level and endothelial progenitor cell mobilization in age-related mac-
ular degeneration patients: safety of intravitreal treatment for vascular ho-
meostasis. J Ocul Pharmacol Ther 2011;27:471e5.
56. Park SJ. Plasma levels of vascular endothelial growth factor and anti-
vascular endothelial growth factor before and after intravitreal injection
of anti-vascular endothelial growth factor. In: Seattle, WA: Annual meeting
of the Association for Research in Vision and Ophthalmology 2013. Abstract
4122.
57. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al.
Randomized, double-masked, sham-controlled trial of ranibizumab for neo-
vascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol
2008;145:239e48.
58. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled
trial of ranibizumab for neovascular age-related macular degeneration: PIER
study year 2. Am J Ophthalmol 2010;150:315e24.
59. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-
Siegel R, et al. Efﬁcacy and safety of monthly versus quarterly ranibizumab
treatment in neovascular age-related macular degeneration: the EXCITE study.
Ophthalmology 2011;118:831e9.
60. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An
optical coherence tomography-guided, variable dosing regimen with intra-
vitreal ranibizumab (Lucentis) for neovascular age-related macular degenera-
tion. Am J Ophthalmol 2007;143:566e83.
61. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al.
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-
related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol
2009;148:43e58.
62. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al.
Safety and efﬁcacy of a ﬂexible dosing regimen of ranibizumab in neovascular
age-related macular degeneration: the SUSTAIN study. Ophthalmology
2011;118:663e71.
63. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb
study to evaluate the safety of ranibizumab in subjects with neovascular age-
related macular degeneration. Ophthalmology 2009;116:1731e9.64. Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Research GroupMartin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Rani-
bizumab and bevacizumab for treatment of neovascular age-related macular
degeneration: two-year results. Ophthalmology 2012;119:1388e98.
65. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, et al. Twelve-month
efﬁcacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal
neovascular age-related macular degeneration. Ophthalmology 2013;120:
1046e56.
66. Sawada T, Kakinoki M, Wang X, Kawamura H, Saishin Y, Ohji M. The efﬁcacy of
bimonthly injection of ranibizumab for age-related macular degeneration for
six months. In: The Association for Research in Vision and Ophthalmology 2013
Annual Meeting, May 5e9 2013. Seattle Abstract 3804.
67. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a
VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:
11393e8.
68. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF
Trap. Br J Ophthalmol 2008;92:667e8.
69. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
et al. Bevacizumab plus irinotecan, ﬂuorouracil, and leucovorin for metastatic
colorectal cancer. N Engl J Med 2004;350:2335e42.
70. Michels S, Rosenfeld PJ, Puliaﬁto CA, Marcus EN, Venkatraman AS. Systemic
bevacizumab (Avastin) therapy for neovascular age-related macular degener-
ation twelve-week results of an uncontrolled open-label clinical study.
Ophthalmology 2005;112:1035e47.
71. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intra-
vitreal bevacizumab (Avastin) for neovascular age-related macular degenera-
tion. Ophthalmology 2006;113:363e72.
72. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
Intravitreal bevacizumab for the management of choroidal neovascularization
in age-related macular degeneration. Am J Ophthalmol 2006;142:1e9.
73. Rich RM, Rosenfeld PJ, Puliaﬁto CA, Dubovy SR, Davis JL, Flynn Jr HW, et al.
Short-term safety and efﬁcacy of intravitreal bevacizumab (Avastin) for neo-
vascular age-related macular degeneration. Retina 2006;26:495e511.
74. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neo-
vascular age-related macular degeneration: an analysis of the 100% 2008
Medicare fee-for-service Part B claims ﬁle. Am J Ophthalmol 2011;151:887e95.
75. Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, et al.
Vascular endothelial growth factor plasma levels before and after treatment of
neovascular age-related macular degeneration with bevacizumab or ranibi-
zumab. Acta Ophthalmol 2012;90:e25e30.
76. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates
erythropoiesis through regulation of adult hepatic erythropoietin synthesis.
Nat Med 2006;12:793e800.
77. Wang YQ, Guo X, Qiu MH, Feng XY, Sun FY. VEGF overexpression enhances
striatal neurogenesis in brain of adult rat after a transient middle cerebral
artery occlusion. J Neurosci Res 2007;85:73e82.
78. Zhang Z, Chopp M. Vascular endothelial growth factor and angiopoietins in
focal cerebral ischemia. Trends Cardiovasc Med 2002;12:62e6.
79. Zachary I. Signaling mechanisms mediating vascular protective actions of
vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:
C1375e86.
